Squamous cell carcinoma of the thyroid: An aggressive tumor associated with tall cell variant of papillary thyroid carcinoma

Modern Pathology

Volumn 13, Issue 7, 2000, Pages 742-746

  Kleer, Celina G ^a,c   Giordano, Thomas J ^a   Merino, Maria J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Squamous cell carcinoma; Tall cell variant; Thyroid neoplasms

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; SPINDLE CELL; SQUAMOUS CELL CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE NECROSIS; TUMOR SUPPRESSOR GENE;

EID: 0033926813     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880129     Document Type: Article

References (27)

1. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 1976;43:207-16.
2. Johnson T, Lloyd RV, Thompson NW, Bierwaltes WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988;12(1):22-7.
3. Ostrowski ML, Merino MJ. Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 1996;20(8):964-74.
4. Bronner MP, LiVolsi VA. Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer. Mod Pathol 1991;4:637-43.
5. Zhuang Z, Berttheau P, Emmert-Buck MR, Liotta LA, Gnarra J, Linehan WM, et al. A new microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter. Am J Pathol 1995;146:620-5.
6. Prakash A, Kukreti SC, Sharma MP. Primary squamous cell carcinoma of the thyroid gland. Int Surg 1968;50(6):538-41.
7. Goldberg HM, Harvey P. Squamous cell cysts of the thyroid. Br J Surg 1956;43:565-9.
8. LiVolsi VA, Merino MJ. Squamous cell in the human thyroid gland. Am J Surg Pathol 1978;2:133-40.
9. Gould VE, Gould NS, Benditt EP. Ultrastructural aspects of papillary and sclerosing carcinomas of the thyroid. Cancer 1972;29:1613-25.
10. Motoyama T, Watanabe H. Simultaneous squamous cell carcinoma and papillary adenocarcinoma of the thyroid gland. Hum Pathol 1983;14:1009-10.
11. Baker SJ, Fearon ER, Nigro J, Hamilton S, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
12. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Wilson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
13. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, et al. Overexpression of p53 as a prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993;17:375-81.
14. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
15. Ito T, Seyama T, Mitzuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71.
16. Lane DP. p53 and human cancers. Br Med Bull 1994;50:582-99.
17. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
18. Banks L, Matlashewski G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159: 529-34.
19. Gannon JV Jr, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
20. Michalovitz D, Halevy O, Oren M. p53 mutations: gains or losses? J Cell Biochem 1991;45:22-9.
21. Nishida T, Nakao K, Hamaji M, Nakahara M, Tsujimoto M. Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 1996;119:568-75.
22. Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, et al. Quantitative growth fraction evaluation with MIB1 and Ki-67 antibodies in breast carcinomas. Am J Clin Pathol 1994;102:171-5.
23. Fielding LP, Fenoglio-Preiser C, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992;70:2367-77.
24. Khine MM, Aung W, Sibbons PD, Howard CV, Clapham E, McGill F, et al. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index. Lab Invest 1994;70: 125-9.
25. Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, Kitsiou E, Stefanaki S, Agnantis N. Growth factors in bladder cancer defined by Ki-67: association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 1993;72:736-9.
26. Weidner N, Moore II DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994;25:337-42.
27. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.